- Went public on TASE (MTLF), Jun 2021
- Raised $6.6M Undisclosed Round, 2025
- Raised $37k grant led by Walkoncemore Foundation, Jul 2025
About
Matricelf is redefining personalized regenerative medicine through its groundbreaking platform for autologous 3D tissue engineering. Founded in 2019 by Alon Sinai, PhD and Professor Tal Dvir at Tel Aviv University, the company develops curative, patient-specific therapies aimed at restoring function and independence in patients with severe neurological injuries. Their lead program targets spinal cord injury (SCI), with preclinical studies showing compelling safety and functional recovery. The company's technology combines patient-derived cells and biomaterials to create an autologous engineered implant tailored to each individual patient, with the goal of restoring neurological function while minimizing the risk of immune rejection. Matricelf's pipeline also includes stroke and traumatic brain injury, with early-stage research exploring additional indications in cardiovascular and retinal diseases.
Funding history · 3 rounds · $6.6M total
Headcount over time
Offices
Q&A
- What is Matricelf's primary focus in regenerative medicine?
- Matricelf is a regenerative medicine company developing personalized, autologous engineered neural tissue for the treatment of spinal cord injury. Their technology combines patient-derived cells and biomaterials to create patient-specific implants.
- When did Matricelf go public and on which exchange?
- Matricelf went public in June 2021 with an IPO on the TASE (Tel Aviv Stock Exchange), raising $7.4 million at a valuation of $22 million.
- What was a significant product development milestone for Matricelf in June 2026?
- In June 2026, Matricelf began manufacturing experimental implants for a spinal cord injury trial, advancing towards their first-in-human trial with the initiation of a GMP manufacturing program.
- What strategic collaboration did Matricelf enter into in March 2026?
- In March 2026, Matricelf entered a strategic collaboration with Japan's CiRA Foundation to advance next-generation regenerative manufacturing.
- What is Matricelf's current employee count?
- Matricelf has 11-50 employees.
- What was a key leadership appointment for Matricelf in February 2026?
- In February 2026, Matricelf appointed Ron Mayron as Chairman of the Board.
- What was the outcome of Matricelf's RNA sequencing results reported in March 2026?
- In March 2026, Matricelf reported positive RNA sequencing results, demonstrating a promising safety profile for its personalized spinal cord implant.
- What is Matricelf's lead program targeting?
- Matricelf's lead program targets spinal cord injury (SCI), with preclinical studies showing compelling safety and functional recovery.
Team · 13
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | matricelf.com/ |
|---|---|
| linkedin.com/company/34957760 |
Identifiers & details
| Legal name | Matricelf Ltd. |
|---|---|
| Founded | 2019-4 |
| Employees (exact) | 15 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2021-06 | TASE | MTLF | $7.4M |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | matricelf.com |
|---|
Certificate / subdomain footprint
| Subdomains | 7 |
|---|